SEC Filings

Form 10-Q
KALA PHARMACEUTICALS, INC. filed this Form 10-Q on 08/09/2018
Document Outline
Entire Document (4019 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - TABLE OF CONTENTS
Page 3 - PART I FINANCIAL INFORMATION
Page 4 - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Page 5 - KALA PHARMACEUTICALS, INC.
Page 6 - KALA PHARMACEUTICALS, INC.
Page 7 - KALA PHARMACEUTICALS, INC.
Page 8 - KALA PHARMACEUTICALS, INC.
Page 9 - KALA PHARMACEUTICALS, INC.
Page 10 - KALA PHARMACEUTICALS, INC.
Page 11 - KALA PHARMACEUTICALS, INC.
Page 12 - KALA PHARMACEUTICALS, INC.
Page 13 - KALA PHARMACEUTICALS, INC.
Page 14 - KALA PHARMACEUTICALS, INC.
Page 15 - KALA PHARMACEUTICALS, INC.
Page 16 - KALA PHARMACEUTICALS, INC.
Page 17 - KALA PHARMACEUTICALS, INC.
Page 18 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations.
Page 19 - STRIDE
Page 20 - Financial Operations Overview
Page 21 - Interest Income
Page 22 - Results of Operations
Page 23 - Interest Income
Page 24 - Research and Development Expenses
Page 25 - Liquidity and Capital Resources
Page 26 - Net Cash Provided by (Used in) Financing Activities
Page 27 - N/A
Page 28 - Contractual Obligations and Commitments
Page 29 - Item 3.Quantitative and Qualitative Disclosures About Market Risk.
Page 30 - Item 1A Risk Factors
Page 31 - N/A
Page 32 - Our limited operating history may make it difficult for you to evaluate the success of our business
Page 33 - N/A
Page 34 - Raising additional capital may cause dilution to our stockholders, restrict our operations or requir
Page 35 - Risks Related to Product Development
Page 36 - If clinical trials of INVELTYS and KPI 121 0.25% or any other product candidate that we develop fail
Page 37 - N/A
Page 38 - If we experience any of a number of possible unforeseen events in connection with our clinical trial
Page 39 - If we experience delays or difficulties in the enrollment of patients in clinical trials, our receip
Page 40 - We may not be successful in our efforts to develop product candidates based on our MPP technology or
Page 41 - Risks Related to the Commercialization of Our Product Candidates
Page 42 - If we are unable to establish sales, marketing and distribution capabilities or enter into sales, ma
Page 43 - We face substantial competition, which may result in others discovering, developing or commercializi
Page 44 - If our contracted manufacturing facilities experience production issues for any reason, we may be un
Page 45 - Even if we are able to commercialize INVELTYS, KPI 121 0.25% or any other product candidate that we
Page 46 - Product liability lawsuits against us could divert our resources and could cause us to incur substan
Page 47 - Risks Related to Our Dependence on Third Parties
Page 48 - N/A
Page 49 - We may enter into collaborations with third parties for the development or commercialization of our
Page 50 - If we are not able to establish collaborations, we may have to alter our development and commerciali
Page 51 - Risks Related to Our Intellectual Property
Page 52 - Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecut
Page 53 - If we are not able to obtain patent term extension in the United States under the Hatch Waxman Act a
Page 54 - inter partes
Page 55 - Obtaining and maintaining patent protection depends on compliance with various procedural, document
Page 56 - Some intellectual property which we own or have licensed may have been discovered through government
Page 57 - We may not be able to protect our intellectual property and proprietary rights throughout the world.
Page 58 - We may be subject to claims by third parties asserting that our employees or we have misappropriated
Page 59 - Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
Page 60 - If the FDA does not conclude that INVELTYS and KPI 121 0.25% satisfy the filing and approval require
Page 61 - The terms of approvals, ongoing regulations and post marketing restrictions for our products may lim
Page 62 - Under the CURES Act and the Trump Administration s regulatory reform initiatives, the FDA s policies
Page 63 - Our relationships with customers and third party payors may be subject, directly or indirectly, to a
Page 64 - Recently enacted and future legislation may affect our ability to commercialize and the prices we ob
Page 65 - N/A
Page 66 - If we or any third party manufacturers we engage in the future fail to comply with environmental, he
Page 67 - We are subject to anti corruption laws, as well as export control laws, customs laws, sanctions laws
Page 68 - The recently passed comprehensive tax reform bill could adversely affect our business and financial
Page 69 - We expect to expand our development, regulatory and manufacturing capabilities and potentially imple
Page 70 - Risks Related to Our Common Stock
Page 71 - An active trading market for our common stock may not be sustained.
Page 72 - Sale of a substantial number of shares of our common stock into the market could cause the market pr
Page 73 - We have incurred and will continue to incur increased costs as a result of operating as a public com
Page 74 - Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Page 75 - Item 6. Exhibits
Page 76 - SIGNATURES
Subdocument 2 - EX-10.1 - EX-10.1
Page 1 - Fourth Amendment
Page 2 - WHEREAS
Page 3 - N/A
Page 4 - IN WITNESS WHEREOF
Page 5 - EXHIBIT D
Subdocument 3 - EX-10.2 - EX-10.2
Page 1 - Exhibit 10.2
Page 2 - Continuous Relationship with the Company Required
Page 3 - providedthat
Page 4 - Transfer Restrictions
Page 5 - Reorganization Events
Page 6 - Miscellaneous
Page 7 - Administration by Board
Page 8 - ANNEX A
Subdocument 4 - EX-10.3 - EX-10.3
Page 1 - Exhibit 10.3
Page 2 - BenefitsExhibit A
Page 3 - Change of Control
Page 4 - Cause
Page 5 - Indemnification
Page 6 - Assignment
Page 7 - N/A
Page 8 - EXHIBIT A
Page 9 - N/A
Page 10 - Exhibit B
Page 11 - BY [METHOD OF DELIVERY]
Page 12 - Separation Date[INSERT SEPARATION DATE]1
Page 13 - et seqet seq
Page 14 - Cooperation
Page 15 - Tax Provision
Page 16 - Applicable Law
Page 17 - [INSERT NAME AND TELEPHONE NUMBER]
Page 18 - Exhibit C
Page 19 - N/A
Page 20 - Non-Competition
Page 21 - Non-Solicitation
Page 22 - Protected Information
Page 23 - Cooperation
Page 24 - Prior InventionsExhibit 3(d)
Page 25 - General
Page 26 - Governing Law
Page 27 - No Waiver of Rights, Powers and Remedies
Page 28 - [NON-COMPETITION, NON-SOLICITATION, CONFIDENTIALITY AND
Page 29 - EXHIBIT 3(d)
Subdocument 5 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 6 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 7 - EX-32.1 - EX-32.1
Page 1 - N/A
Subdocument 8 - EX-32.2 - EX-32.2
Page 1 - N/A
XBRL Item - EX-101.INS - EX-101.INS (What's this?)
XBRL Item - EX-101.SCH - EX-101.SCH (What's this?)
XBRL Item - EX-101.CAL - EX-101.CAL (What's this?)
XBRL Item - EX-101.DEF - EX-101.DEF (What's this?)
XBRL Item - EX-101.LAB - EX-101.LAB (What's this?)
XBRL Item - EX-101.PRE - EX-101.PRE (What's this?)
XBRL Viewer